Can visual hallucinations be among the neuropsychological manifestations of systemic mastocytosis?: A geriatric case

 

Ozge Kilica, Ugur Eser Yilmazb, Zeynep Komeslic, A. Cenk Ercana, Mustafa Cetinerd

 

aKoc University Hospital, Department of Psychiatry, Istanbul; 

bKoc University School of Medicine, Istanbul; 

cKoc University Hospital, Department of Internal Medicine, Istanbul;

dAcibadem Maslak Hospital, Department of Haematology, Istanbul, Turkey

 

 

Abstract

Mast cells are considered sensors of environmental and emotional stress, exist in all body parts and are related to the pathway from stress to inflammation. Mastocytosis defines a rare disease characterized by the accumulation of abnormal mast cells in multiple organs. Here, we present a 77-year-old woman with a background of aggressive systemic mastocytosis who developed impaired cognition, depression, anxiety, visual hallucinations, delusions, and insomnia. Symptoms alleviated only after initiating midostaurin, a tyrosine kinase inhibitor. Systemic mastocytosis should be kept in mind when visual hallucinations are concomitant with chronic or recurrent multi-system disturbances and do not benefit from treatment as usual.

Keywords: mastocytosis, mast cell, brain fog, depression, anxiety, visual hallucination

 

 

Introduction

Mast cells (MC) are considered sensors of environmental and emotional stress (1), existing in all body parts, and are related to inflammation. Mastocytosis defines a group of rare disorders characterized by neoplastic proliferation and accumulation of abnormal MCs in organ systems. Pathogenesis includes chronic, episodic MC-mediator release and excessive MC infiltration. Diagnostic criteria of systemic mastocytosis (SM) can be found in Table 1.

Depression, anxiety, irritability, emotional instability, deficits in attention, concentration, and memory are common in SM (2, 3) and affect patients’ quality of life (4) enormously. This case report presents a sporadic disease with multiple neuropsychological manifestations (NM) and discusses its relevance to psychiatry. Patient informed consent and assent were obtained.

     

Case presentation

A 77-year-old woman presented to our internal medicine outpatient clinic with shortness of breath, palpitations, and watery diarrhea. Medical history revealed abdominal pain, diarrhea, and weight loss five years ago that failed a diagnosis. Stool investigations, upper/lower gastrointestinal endoscopies were unremarkable. She was admitted for abdominal distention and a petechial rash. A computerized abdominal tomography scan revealed free fluid, hepatomegaly, splenomegaly, lymph nodes near the hepatic hilum. Paracentesis revealed serum-ascites albumin gradient of 1,5 g/dL, consistent with portal hypertension. Cytopenia, elevated alkaline-phosphatase (1130 U/L) and serum tryptase increased INR (1.41), hypoalbuminemia (3.1 g/dL), negative viral/autoimmune hepatitis markers, absence of drug allergies and substance use were noted. A positron emission tomography-computed tomography (PET-CT) revealed “possible bone marrow activation/infiltration.” Liver biopsy, bone marrow aspiration revealed CD117-positive MC infiltration. Target cell population stained with MC tryptase, consistent with aggressive systemic mastocytosis (ASM). Imatinib, a tyrosine kinase inhibitor (TKI), was trialed 400mg q.d. Without relief. She was discharged on partial remission.

 

Five months later, she suffered from hallucinations, confusion, severe agitation, insomnia, weight loss, difficulty walking, and was admitted to our internal medicine ward. Psychiatry was consulted for severe insomnia without sleep for days. In the two months prior, she was forgetful, depressed, and anxious, impairing functionality. She was brought to another psychiatry clinic and was prescribed clozapine 25mg and quetiapine 50mg q.d. Without relief. Psychiatric history revealed one depressive episode 10 years ago, remitted on an ongoing treatment of escitalopram 10mg and bromazepam 6mg q.d. Since; and another short depressive episode 35 years ago. No suicidal thoughts were reported. Mental state examination revealed impaired orientation, concentration, and memory; depressive mood, emotional lability; delusions about ‘people stealing her money, planning her murder, her caretaker having an affair with her spouse,’ visual hallucinations, difficulties articulating and recalling common words. She denied mental disorders before 42 years of age, prior cognitive decline, neurological disorders, and family history of mental disorders. Neurological examination and cranial MRI were normal. Due to her confusion and psychomotor agitation, neuropsychological testing was not possible. Medications included H1, H2 histamine antagonists, cromolyn sodium (100 mg), imatinib, and melatonin 6mg daily. She was prescribed quetiapine up to 75mg q.d. Moderately alleviating insomnia, while hallucinations, delusions, psychomotor agitation persisted. Ten drops of haloperidol t.i.d and risperidone 1mg q.d. were trialed without therapeutic relief. Imatinib was switched to midostaurin 50mg (FDA-approved TKI for ASM)(5) when obtained, which improved consciousness, sleep and psychomotor agitation in four days. She was discharged on midostaurin 100mg b.i.d., escitalopram 10mg, bromazepam 6mg, and risperidone 1 mg q.d. In the first week follow-up, no hallucinations, paranoid ideation, or insomnia were observed. Risperidone was stopped, escitalopram 10mg and bromazepam 6mg q.d. was continued. She described complete amnesia for the seven-week hospitalization.  

 

Discussion

This patient presented with impaired cognition, depressive, anxiety, psychotic disorder, and insomnia interfering with daily functions; without a referral investigating an underlying disease. The combination of impairment in attention, concentration, short and long-term memory – called ‘brain fog’ – presents in two-fifths of SM cases (6) as a primary complaint besides depression (7). The pathway from ‘stress’ to brain fog (8, 9) could include MCs located along blood vessels at the level of the blood-brain-barrier (10) releasing inflammatory molecules (adipocytokines, histamine), microglial stimulation, and focal brain inflammation (7). Secondly, MCs in the blood-brain-barrier can alter permeability, allowing lymphocyte attraction through chemotactic substances (11). Reduced attention and concentration were reported independent of depression (6, 12).

 

We do not relate the depressive episodes 35 and 10 years ago to SM as the former completely remitted for 20 years, and the latter differentiated in phenomenology from this episode through the absence of recurrent multi-system disturbances and acutely impaired cognition. Depression and anxiety appear in 40-60 % of SM cases (13). Depression is suggested as linked to tryptophan metabolism(13) and independent of somatic symptoms( 14). To screen depression and anxiety in SM, hospital anxiety and depression scale; for treatment of depression and anxiety in SM,  (15) masitinib  (a TKI) is suggested to be beneficial (14).

 

Our patient presented with extraordinary betrayal delusions and visual hallucinations. Two earlier case studies report persecutory delusions in mast cell leukemia, the rarest, and the most aggressive category of SM (16, 17). Although reported as observations, visual hallucination was not discussed to this extent regarding the differential diagnosis of a geriatric patient. To our knowledge, betrayal delusions were not previously reported. The patient has no pre-existing cognitive impairment, neurological or psychotic symptoms. The acute onset excluded Alzheimer’s, frontotemporal, and Lewy body neurocognitive disorder. Acute cerebrovascular disease and brain injury were eliminated with an unremarkable brain MRI. Although delusions occur, visual hallucinations are rare in primary depressive, bipolar or psychotic disorders. No evidence from the history, examination, or laboratory findings could be linked to another medical conditions, and symptoms alleviated only after initiating midostaurin, thus excluding delirium. Evaluations yielded a diagnosis of neurocognitive disorder with behavioral disturbance, depressive, anxiety, and psychotic disorders due to ASM. This report adds to the knowledge of visual hallucination and betrayal delusions in the NM of SM.

 

Conclusion

SM could present with neurocognitive, depressive, anxiety, and psychotic symptoms, which should be considered in diagnosing neurocognitive and psychiatric disorders with chronic or recurrent multisystem disturbances and mediator-induced symptoms of unclear unifying origin. Specialists in neurology and psychiatry should perform specific examinations, including a cerebral scan or MRI (3); a systematic investigation of depression, anxiety, and cognitive impairment (13). The treatment of NM in SM is primarily based on the treatment of mastocytosis.

 

References

[1]       Theoharides TC. Mast cells and stress—a psychoneuroimmunological perspective. Journal of Clinical Psychopharmacology. 2002;22(2):103-8.

[2]       Valent P, Akin C, Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood. 2017;129(11):1420-7.

[3]       Horan RF, Austen KF. Systemic mastocytosis: retrospective review of a decade’s clinical experience at the Brigham and Women’s Hospital. J Invest Dermatol. 1991;96(3):5S-14S.

[4]       Moura DS, Georgin-Lavialle S, Gaillard R, Hermine O. Neuropsychological features of adult mastocytosis. Immunol Allergy Clin North Am. 2014;34(2):407-22.

[5]       Valent P, Akin C, Gleixner KV, Sperr WR, Reiter A, Arock M, et al. Multidisciplinary challenges in mastocytosis and how to address with personalized medicine approaches. International Journal of Molecular Sciences. 2019;20(12):2976.

[6]       Kasamon YL, Ko CW, Subramaniam S, Ma L, Yang Y, Nie L, et al. FDA approval summary: midostaurin for the treatment of advanced systemic mastocytosis. The Oncologist. 2018;23(12):1511-9.

[7]       Moura DS, Sultan S, Georgin-Lavialle S, Barete S, Lortholary O, Gaillard R, et al. Evidence for cognitive impairment in mastocytosis: prevalence, features and correlations to depression. PLoS One. 2012;7(6):e39468.

[8]       Theoharides TC, Stewart JM, Hatziagelaki E. Brain “fog,” inflammation and obesity: key aspects of neuropsychiatric disorders improved by luteolin. Frontiers in Neuroscience. 2015;9:225.

[9]       Ghosh D, Bernstein JA. Systemic and localized seminal plasma hypersensitivity patients exhibit divergent immunologic characteristics. Journal of Allergy and Clinical Immunology. 2014;134(4):969-72. e3.

[10]     Russell N, Jennings S, Jennings B, Slee V, Sterling L, Castells M, et al. The Mastocytosis Society survey on mast cell disorders: part 2—patient clinical experiences and beyond. The Journal of Allergy and Clinical Immunology: In Practice. 2019;7(4):1157-65. e6.

[11]     Khalil M, Ronda J, Weintraub M, Jain K, Silver R, Silverman A-J. Brain mast cell relationship to neurovasculature during development. Brain Research. 2007;1171:18-29.

[12]     Theoharides T. Mast cells: the immune gate to the brain. Life Sciences. 1990;46(9):607-17.

[13]     Moura DS, Georgin-Lavialle S, Gaillard R, Hermine O. Neuropsychological features of adult mastocytosis. Immunology and Allergy Clinics. 2014;34(2):407-22.

[14]     Georgin-Lavialle S, Moura DS, Salvador A, Chauvet-Gélinier J-C, Launay J-M, Damaj G, et al. Mast cells’ involvement in inflammation pathways linked to depression: evidence in mastocytosis. Molecular Psychiatry. 2016;21(11):1511.

[15]     Moura DS, Sultan S, Georgin-Lavialle S, Pillet N, Montestruc F, Gineste P, et al. Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy. PLoS One. 2011;6(10):e26375.

[16]     Georgin-Lavialle S, Gaillard R, Moura D, Hermine O. Mastocytosis in adulthood and neuropsychiatric disorders. Translational Research. 2016;174:77-85. e1.

[17]     Dasanu C, Davis L, Bauer F. Aleukemic leukemia presenting with paranoid psychosis. Connecticut Medicine. 2013;77(9):537-9.

[18]     Dasanu C, Davis L, Bauer F. Sustained paranoid psychosis in a patient with mast cell leukemia and decreased serotonin level. Journal of Postgraduate Medicine. 2013;59(2):161.